Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Cancer- and cancer treatment-related conditions
Stage/Subtype:  graft versus host disease
Trial Type:  Supportive care
Results 1-25 of 64 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
Donor Peripheral Blood Stem Cell transplantation Followed by Lenalidomide and Sirolimus in Treating Patients With High-Risk Multiple Myeloma
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 18 to 70
Trial IDs: IUCRO-0307, NCI-2011-00266, 1012-24, 1105005328, NCT01303965
Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide after Donor Bone Marrow Transplant in Treating Patients with Hematological Malignancies
Phase: Phase II, Phase I
Type: Supportive care, Treatment
Age: 6 months to 85
Trial IDs: J1151, NCI-2014-01339, CR00000875, NA_00048378, NA_00048378 / CIR00006178, NCI-2014-00310, NCT01342289
Alpha 1 Anti-Trypsin in Treating Patients with Acute Graft-Versus-Host Disease
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: not specified
Trial IDs: 2571.00, NCI-2011-03805, 2571, NCT01523821
Chemotherapy and Donor Lymphocytes in Treating Older Patients with High-Risk Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 55 and over
Trial IDs: Pro00043247, NCI-2014-00663, NCT02046122
Plerixafor in Improving Blood Cell Counts After Donor Stem Cell Transplant in Patients With High Risk Hematologic Malignancies
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 to 65
Trial IDs: Pro00024433, NCI-2013-01897, Amd021_Pro00024433, NCT01280955
Ofatumumab and Prednisone in Treating Patients With Chronic Graft-Versus-Host Disease
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: MCC-17071, NCI-2012-02451, 00008286, NCT01680965
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Chronic Graft Versus Host Disease
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 and over
Trial IDs: PCYC-1129-CA, NCI-2014-01591, NCT02195869
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy using Sirolimus in Treating Patients with Hematologic Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Sirolimus, Cyclosporine, and Mycophenolate Mofetil In Preventing Graft-Versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
Two Step Donor Stem Cell Transplant in Treating Patients With High-Risk Hematological Malignancies
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 08D.85, NCI-2012-00407, 2007-61, NCT01315132
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD after Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients with Hematological Malignancies
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 0 to 75
Trial IDs: 2546.00, NCI-2011-03828, NCT01527045
Clobetasol Propionate in Treating Patients with Oral Chronic Graft-Versus-Host Disease
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 12 to 99
Trial IDs: 12-C-0068, NCI-2013-01531, 120068, P11922, NCT01557517
Pomalidomide in Treating Patients with Chronic Graft-Versus-Host Disease
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 18 to 75
Trial IDs: 12-C-0197, NCI-2013-01552, 120197, P12974, NCT01688466
Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2661.00, NCI-2013-00538, 2661, NCT01812252
Maraviroc in Preventing Graft-Versus-Host Disease in Patients With Hematologic Malignancies Undergoing Unrelated Donor Stem Cell Transplant
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: UPCC 04712, NCI-2013-00464, NCT01785810
Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care
Age: 21 and under
Trial IDs: 2660.00, NCI-2013-00958, NCT01858740
Cyclophosphamide in Preventing Graft-versus-Host Disease after Donor Stem Cell Transplant in Patients with Hematopoietic Malignancies
Phase: Phase II
Type: Supportive care
Age: 19 to 65
Trial IDs: UAB1286, NCI-2015-00251, NCT02065154
Topical Sirolimus in Treating Patients with Refractory Oral Chronic Graft-versus-Host Disease
Phase: Phase II
Type: Supportive care
Age: 4 and over
Trial IDs: 14-090, NCI-2014-01564, NCT02123966
Tocilizumab for Chronic Graft-versus-Host Disease Treatment
Phase: Phase II
Type: Supportive care
Age: 18 and over
Trial IDs: 9130, NCI-2014-01204, NCT02174263
Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Phase: Phase II
Type: Supportive care
Age: 18 to 75
Trial IDs: BMTCTN1203, NCI-2014-01917, U01HL069294, NCT02208037
Pasireotide in Reducing Gastrointestinal Toxicity from Chemotherapy and Radiation in Patients Undergoing a Donor Stem Cell Transplant
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: 18 and over
Trial IDs: Pro00051736, NCI-2014-02316, NCT02215070
Safety and Efficacy of Human Myeloid Progenitor Cells (CLT-008) During Chemotherapy for Acute Myeloid Leukemia
Phase: Phase II
Type: Supportive care
Age: 55 and over
Trial IDs: CLT008-03, NCI-2014-02461, NCT02282215
Start Over